Rapid, cost-effective, sensitive and quantitative detection of Acinetobacter baumannii from pneumonia patients
-
B Nomanpour
,
A Ghodousi
,
A Babaei
,
HR Abtahi
,
M Tabrizi
,
M Feizabadi
Abstract
Background and Objectives: Pneumonia with Acinetobacter baumannii has a major therapeutic problem in health care settings. Decision to initiate correct antibiotic therapy requires rapid identification and quantification of organism. The aim of this study was to develop a rapid and sensitive method for direct detection of A. baumannii from respiratory specimens.
Materials and Methods: A Taqman real time PCR based on the sequence of blaoxa-51 was designed and used for direct detection of A. baumannii from 361 respiratory specimens of patients with pneumonia. All specimens were checked by conventional bacteriology in parallel.
Results: The new real time PCR could detect less than 200 cfu per ml of bacteria in specimens. There was agreement between the results of real time PCR and culture (Kappa value 1.0, p value < 0.001). The sensitivity, specificity and predictive values of real time PCR were 100%. The prevalence of A. baumannii in pneumonia patients was 10.53 % (n = 38). Poly-microbial infections were detected in 65.71% of specimens.
Conclusion: Acinetobacter baumannii is the third causative agent in nosocomial pneumonia after Pseudomonas aeroginosa (16%) and Staphylococcus aureus (13%) at Tehran hospitals. We recommend that 104 CFU be the threshold for definition of infection with A. baumannii using real time PCR.
Kollef MH. Review of recent clinical trials of hospital-acquired pneumonia and ventilator associated pneumonia: a perspective from academia. Clin Infect Dis 2010; 1: 51 (Suppl 1) S29-35.
Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents 2008; 32: 106-119.
Peleg AY, Seifert H, Paterson DL.Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-582.
Rungruanghiranya S, Somboonwit C, Kanchanapoom T. Acinetobacter Infection in the Intensive Care Unit. J Infect Dis Antimicrob Agents 2005; 22: 77-92.
Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010; 23: 332-339.
Perez F, Endimiani A, Bonomo RA. Why are we afraid of Acinetobacter baumannii? Expert Rev Anti Infect Ther 2008; 6: 269-271.
Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43(Suppl. 2): S100-S105.
Torres A. Implementation of guidelines on hospital- acquired pneumonia: is there a clinical impact on outcome? Chest 2005; 128: 1900-802.
Craven DE. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator- associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
Huang Q, Hu Q, Li Q. Identification of 8 food-borne pathogens by multicolor combinational probe coding technology in a single real-time PCR. Clin Chem 2007;53: 1741-1748.
Mackay IM. Real-time PCR in the microbiology laboratory. Clin Microbiol Infect 2004; 10: 190-212.
Feizabadi MM, Fathollahzadeh B, Taherikalani M,nosocomial pathogenic Pseudomonas aeruginosa and Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and distribution of bla OXA genes among Acinetobacter spp. Isolated from patients at Tehran hospitals. Jpn J Infect Dis 2008; 61:274-278.
Niederman MS. The clinical diagnosis of ventilator- associated pneumonia. Respir Care 2005; 50: 788-796.
Schreckenberger PC, Daneshvar MI, Weyant RS, et al. (2003): Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative Gram-negative rods. In Murray PR, Baron EJ, Jorgensen JA, et al. Manual of Clinical Microbiology (9th ed.). Washington DC: American Society Microbiology. pp.749-79.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults. Clin Infect Dis 44 (Suppl.2): S2 = S72.
Feizabadi MM, Majnooni A, Nomanpour B, Fatolahzadeh B, Raji N, Delfani S, et al. Direct detection of Pseudomonas aeruginosa from patients with healthcare associated pneumonia by real time PCR. Infect Genet Evol 2010; 10: 1247-1251.
Mehndiratta M, Palanichamy JK, Ramalingam P, Pal A, Das P, Sinha S, et al. Fluorescence acquisition during hybridization phase in quantitative real-time PCR improves specificity and signal-to-noise ratio.Biotechniques 2008; 45: 625-626 628, 630 passim.
Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001; 29: e45.
Maragakis LL, Perl TM.Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46: 1254-1263.
Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG; Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-668.
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
Chawla R. Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator associated pneumonia in Asian countries. Am J Infect Control 2008; 36 (4 Suppl): S93-100.
Park YK, Peck KR, Cheong HS, Chung DR, Song JH, Ko KS. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009;15: 1325-1327.
Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 2005;11: 1218-1224.
Keum KC, Yoo SM, Lee SY, Chang KH, Yoo NC, Yoo WM, et al. DNA microarray-based detection of nosocomial pathogenic Pseudomonas aeruginosa andAcinetobacter baumannii. Mol Cell Probes 2006; 20:42-50.
Brown S, Young HK, Amyes SGB. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin Microbiol Infect 2005;11: 15-23.
Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. et al. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol 2006; 44: 2974-2976.
Guay DR. Guidelines for the management of adults with health care-associated pneumonia: implications for nursing facility residents. Consult Pharm 2006;21:719-725.
Fàbregas N, Ewig S, Torres A, El-Ebiary M, Ramirez J, de La Bellacasa JP, et al. Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. Thorax 1999; 54: 867-873.
Torres A, El-Ebiary M. Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia. Chest 2000; 117(4 Suppl 2); 198S-202S.
Mera RM, Miller LA, Amrine-Madsen H, Sahm DF.Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010; 16: 209-215.
| Files | ||
| Issue | Vol 3 No 4 (2011) | |
| Section | Articles | |
| Keywords | ||
| HAP VAP Acinetobacter baumannii Real time PCR Pneumonia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
